Literature DB >> 15661536

TSC1-2 tumour suppressor and regulation of mTOR signalling: linking cell growth and proliferation?

Greg M Findlay1, Laura S Harrington, Richard F Lamb.   

Abstract

Understanding the relationship between growth and proliferation in multicellular organisms requires identification of the key regulators of growth control, and an understanding of how they regulate growth and how growth is linked to cell proliferation. Recent progress in understanding the mechanisms of growth control indicates that the tuberous sclerosis complex tumour-suppressor TSC1-2 serves as a point of integration between growth-stimulatory and growth-suppressive signalling upstream of a small GTPase, Rheb. However, Rheb-induced growth might not explain the additional effects of TSC1-2 upon cell proliferation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15661536     DOI: 10.1016/j.gde.2004.11.002

Source DB:  PubMed          Journal:  Curr Opin Genet Dev        ISSN: 0959-437X            Impact factor:   5.578


  15 in total

1.  Rag GTPases and AMPK/TSC2/Rheb mediate the differential regulation of mTORC1 signaling in response to alcohol and leucine.

Authors:  Ly Q Hong-Brown; C Randell Brown; Abid A Kazi; Maithili Navaratnarajah; Charles H Lang
Journal:  Am J Physiol Cell Physiol       Date:  2012-03-21       Impact factor: 4.249

2.  DNMT3b Modulates Melanoma Growth by Controlling Levels of mTORC2 Component RICTOR.

Authors:  Goran Micevic; Viswanathan Muthusamy; William Damsky; Nicholas Theodosakis; Xiaoni Liu; Katrina Meeth; Emily Wingrove; Manjula Santhanakrishnan; Marcus Bosenberg
Journal:  Cell Rep       Date:  2016-02-25       Impact factor: 9.423

3.  Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma.

Authors:  Evangelia Peponi; Elias Drakos; Guadalupe Reyes; Vasiliki Leventaki; George Z Rassidakis; L Jeffrey Medeiros
Journal:  Am J Pathol       Date:  2006-12       Impact factor: 4.307

4.  Regression of subependymal giant cell astrocytomas with RAD001 (Everolimus) in tuberous sclerosis complex.

Authors:  Michal Yalon; L Ben-Sira; S Constantini; A Toren
Journal:  Childs Nerv Syst       Date:  2010-08-12       Impact factor: 1.475

5.  Abnormal growth of smooth muscle-like cells in lymphangioleiomyomatosis: Role for tumor suppressor TSC2.

Authors:  Elena A Goncharova; Dmitriy A Goncharov; Matthew Spaits; Daniel J Noonan; Ekaterina Talovskaya; Andrew Eszterhas; Vera P Krymskaya
Journal:  Am J Respir Cell Mol Biol       Date:  2006-01-19       Impact factor: 6.914

6.  Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors.

Authors:  Chelsey Woodrum; Alison Nobil; Sandra L Dabora
Journal:  J Transl Med       Date:  2010-02-10       Impact factor: 5.531

Review 7.  Smooth muscle-like cells in pulmonary lymphangioleiomyomatosis.

Authors:  Vera P Krymskaya
Journal:  Proc Am Thorac Soc       Date:  2008-01-01

8.  Mammalian target of rapamycin repression by 3,3'-diindolylmethane inhibits invasion and angiogenesis in platelet-derived growth factor-D-overexpressing PC3 cells.

Authors:  Dejuan Kong; Sanjeev Banerjee; Wei Huang; Yiwei Li; Zhiwei Wang; Hyeong-Reh Choi Kim; Fazlul H Sarkar
Journal:  Cancer Res       Date:  2008-03-15       Impact factor: 12.701

9.  Evolution of the TOR pathway.

Authors:  Teunis J P van Dam; Fried J T Zwartkruis; Johannes L Bos; Berend Snel
Journal:  J Mol Evol       Date:  2011-11-05       Impact factor: 2.395

10.  Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models.

Authors:  Nancy Lee; Chelsey L Woodrum; Alison M Nobil; Aubrey E Rauktys; Michael P Messina; Sandra L Dabora
Journal:  BMC Pharmacol       Date:  2009-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.